Literature DB >> 9439535

Total energy expenditure in patients with small-cell lung cancer: results of a validated study using the bicarbonate-urea method.

E Gibney1, M Elia, S A Jebb, P Murgatroyd, G Jennings.   

Abstract

The bicarbonate-urea method for measuring CO2 production was applied to eight free-living patients (mean age, 68 +/- 10 years; mean weight, 69 +/- 10 kg; mean height, 1.65 +/- 0.10 m) with unresectable small-cell lung cancer for a period of 1 day (n = 5) or 2 days (n = 3). The basal metabolic rate (BMR) was measured in all subjects. The technique was first validated against whole-body indirect calorimetry over an additional 24-hour period in five of these subjects. The bicarbonate-urea method predicted net CO2 production to be 102.1% +/- 3.4% of that measured by whole-body indirect calorimetry, and energy expenditure, 101.5% +/- 3.8% of the measured calorimeter value (8.1 +/- 1.6 MJ/d). The 24-hour recovery of label in CO2 excreted by the body was 95.6% +/- 0.5%. In free-living conditions, the bicarbonate-urea method predicted energy expenditure to be 9.0 +/- 2.6 MJ/d. BMR was elevated by a mean of 6% (P < .05) compared with the Schofield standards. The physical activity level ([PAL] the ratio of total energy expenditure [TEE] to BMR) was variable (1.15 to 1.87), but the mean value was only 1.36 +/- 0.22, considerably less than that of moderately active healthy subjects with estimated PAL values of 1.55 (P < .05) to 1.65 (P < .01) and the mean results obtained by doubly labeled water (previous studies) in healthy age- and sex-matched subjects. This is the first time a tracer method for measuring CO2 production and energy expenditure has been validated against whole-body 24-hour indirect calorimetry in patients with lung cancer or a systemic inflammatory reaction. The agreement between the two methods is similar to that observed in normal subjects. This is also the first time a tracer method has been used to measure energy expenditure in free-living patients with lung cancer. The results suggest that TEE and the energy requirements necessary to maintain energy balance were not increased despite basal hypermetabolism, because of the associated decrease in physical activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9439535     DOI: 10.1016/s0026-0495(97)90140-2

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  16 in total

Review 1.  Thalidomide and cancer cachexia: old problem, new hope?

Authors:  M Stroud
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

2.  Total energy expenditure in patients with colorectal cancer: associations with body composition, physical activity, and energy recommendations.

Authors:  Sarah A Purcell; Sarah A Elliott; Peter J Walter; Tom Preston; Hongyi Cai; Richard J E Skipworth; Michael B Sawyer; Carla M Prado
Journal:  Am J Clin Nutr       Date:  2019-08-01       Impact factor: 7.045

Review 3.  Key determinants of energy expenditure in cancer and implications for clinical practice.

Authors:  S A Purcell; S A Elliott; V E Baracos; Q S C Chu; C M Prado
Journal:  Eur J Clin Nutr       Date:  2016-06-08       Impact factor: 4.016

Review 4.  The "parallel pathway": a novel nutritional and metabolic approach to cancer patients.

Authors:  Maurizio Muscaritoli; Alessio Molfino; Gianfranco Gioia; Alessandro Laviano; Filippo Rossi Fanelli
Journal:  Intern Emerg Med       Date:  2010-07-02       Impact factor: 3.397

Review 5.  Energy expenditure and aging.

Authors:  Todd M Manini
Journal:  Ageing Res Rev       Date:  2009-08-19       Impact factor: 10.895

Review 6.  Computational modeling of cancer cachexia.

Authors:  Kevin D Hall; Vickie E Baracos
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2008-05       Impact factor: 4.294

Review 7.  Nutritional support in multimodal therapy for cancer cachexia.

Authors:  Ingvar Bosaeus
Journal:  Support Care Cancer       Date:  2008-01-15       Impact factor: 3.603

8.  [Diagnosis of and therapy for hepatocellular carcinoma].

Authors:  T F Greten; N P Malek; S Schmidt; J Arends; P Bartenstein; W Bechstein; T Bernatik; M Bitzer; A Chavan; M Dollinger; D Domagk; O Drognitz; M Düx; S Farkas; G Folprecht; P Galle; M Geißler; G Gerken; D Habermehl; T Helmberger; K Herfarth; R T Hoffmann; M Holtmann; P Huppert; T Jakobs; M Keller; J Klempnauer; F Kolligs; J Körber; H Lang; F Lehner; F Lordick; A Lubienski; M P Manns; A Mahnken; M Möhler; C Mönch; P Neuhaus; C Niederau; M Ocker; G Otto; P Pereira; G Pott; J Riemer; K Ringe; U Ritterbusch; E Rummeny; P Schirmacher; H J Schlitt; K Schlottmann; V Schmitz; A Schuler; H Schulze-Bergkamen; D von Schweinitz; D Seehofer; H Sitter; C P Straßburg; C Stroszczynski; D Strobel; A Tannapfel; J Trojan; I van Thiel; A Vogel; F Wacker; H Wedemeyer; H Wege; A Weinmann; C Wittekind; B Wörmann; C J Zech
Journal:  Z Gastroenterol       Date:  2013-11-15       Impact factor: 2.000

Review 9.  Non-surgical oncology - Guidelines on Parenteral Nutrition, Chapter 19.

Authors:  J Arends; G Zuercher; A Dossett; R Fietkau; M Hug; I Schmid; E Shang; A Zander
Journal:  Ger Med Sci       Date:  2009-11-18

10.  Cancer cachexia: impact, mechanisms and emerging treatments.

Authors:  Vanessa C Vaughan; Peter Martin; Paul A Lewandowski
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-10-25       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.